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1122-170 Expression of Tob by Human Coronary Arteries and 
BMP-Mediated Stimulation of Coronary Artery 
Endothelial Cell Proliferation
Jun Xu, Terence M. Doherty, Di Chen, Shuang Chen, Pinky V. Tripathi, Suzhen Guo, Ejaz 
Ahmad, Lorraine A. Fitzpatrick, Tadashi Yamamoto, Prediman K. Shah, Tripathi B. 
Rajavashisth, Cedars-Sinai Medical Center, Los Angeles, CA, David Geffen School of 
Medicine at UCLA, Los Angeles, CA
Background: Little is known regarding the role of bone morphogenetic protein (BMP)
signaling that control vascular cell growth during normal homeostasis and in arterial
pathologies, notably atherosclerosis and arterial calcification. Here we tested the hypoth-
eses that Tob, an antiproliferative protein that negatively regulates BMP signaling, is
expressed in human coronary arteries and in cultured human coronary artery endothelial
cells (ECs) and that BMP2 stimulates proliferation in cultured ECs. Methods and
Results: Immunohistochemical localization showed abundant expression of Tob in ECs
of normal human arteries. We therefore determined expression of Tob and BMP receptor
(BMPR)-IA, -IB, and II in cultured ECs at baseline and stimulated with BMP2 (300 ng/mL
for 6 hr). Experiments were also performed in the presence of the proteasome inhibitor
epoxomicin that enhances BMP signaling by preventing degradation of BMP signaling
pathway components. ECs expressed Tob and BMPR-IA and -II, but did not express
BMPR-IB. Stimulation with either BMP2 or epoxomicin resulted in a significant increase
in expression of BMPR-IA and BMPR-II (p < 0.01 for both BMP2 and epoxomicin), but
there was no change in Tob mRNA. Stimulation of ECs with either BMP2 or epoxomicin
significantly increased proliferation measured by both a colorimetric proliferation assay (p
< 0.001 for both BMP2 and epoxomicin; n = 5) and by proliferating cell nuclear antigen
(PCNA) assay (p < 0.0.05 and 0.006; n = 3) after 48 hr in a dose-dependent manner. Tox-
icity was observed at high doses of epoxomicin. Conclusions: The antiproliferative BMP
pathway inhibitor Tob and BMPR-IA and II are abundantly expressed by human coronary
artery ECs both in vitro and in vivo. Expression of BMPR but not Tob transcripts are
affected by both BMP2 and epoxomicin. BMP2 may regulate EC proliferation, suggesting
a possible role in the growth of ECs during normal homeostasis and in arterial patholo-
gies involving EC denudation or proliferation. Since Tob has been implicated as an anti-
proliferative regulator in many other cell types, it may also regulates EC proliferation via a
mechanism that is not dependent on altered transcription of Tob in response to BMP
stimulation.
1122-171 Atherogenic Low-Density Lipoprotein Impairs Vascular 
Endothelial Cell Survival by Disrupting the FGF2-PI3K-
Akt Autoregulatory Loop
Wei Jiang, Jonathan Lu, Jun-Hai Yang, Po-Yuang Chang, Yuan-Teh Lee, Marco Marcelli, 
Philip D. Henry, Warren S. Liao, Chu-Huang Chen, Baylor College of Medicine, Houston, 
TX, The University of Texas M. D. Anderson Cancer Center, Houston, TX
Background:
Atherogenic LDL, such as circulating electronegative LDL and oxidized LDL (oxLDL), can
inhibit proliferation and induce apoptosis in vascular endothelial cells (EC). Fibroblast
growth factor 2 (FGF2) stimulates phosphatidylinositol 3-kinase (PI3K), which in turn acti-
vates Akt, a protein kinase that regulates cell survival. This study was designed to inves-
tigate how oxLDL interferes with signal transduction along the FGF2-PI3K-Akt pathway.
Methods:
The interrelationship between FGF2 and Akt was examined in cultured bovine aortic EC
(BAEC). To investigate further the role of endogenous FGF2 in EC survival,
BAEC[FGF2(+)] and BAEC[FGF2(–)] cell lines were established by stable transfection of
BAEC with FGF2 sense and antisense cDNAs.
Results:
In cultured BAEC, oxLDL (50 µg/mL) inhibited FGF2 transcription and Akt phosphoryla-
tion, leading to marked apoptosis. Consistent with the cell-survival properties of Akt,
PI3K inhibitor wortmannin (25-200 nM) also inhibited FGF2 expression and induced apo-
ptosis in a concentration-dependent manner. Stable overexpression of FGF2 in
BAEC[FGF2(+)] greatly enhanced Akt phosphorylation, rendering the cells resistant to
oxLDL. In contrast, deprivation of endogenous FGF2 in BAEC[FGF2(–)] led to reduced
Akt phosphorylation and enhanced spontaneous apoptosis. Inhibition of FGF2 protein
synthesis by the antisense RNA also led to inhibition of FGF2 transcription in
BAEC[FGF2(–)], suggesting that endogenously produced FGF2 may be the most impor-
tant stimulator of its own induction in the low-serum, mitogen-free culture system. Fur-
thermore, G2/M transition in the cell cycle and DNA synthesis were severely inhibited in
BAEC[FGF2(–)], limiting proliferation. In contrast, unlike the parental BAEC,
BAEC[FGF2(+)] were resistant to the inhibitory effects of oxLDL on G2/M transition and
DNA synthesis.
Conclusion:
EC survival depends on continuous activation of the PI3K-Akt pathway by endogenous
FGF2, which is required for its own induction in the manner of an autocrine. Maintenance
of the integrity of the FGF2-PI3K-Akt autoregulatory loop is essential for EC survival in
the presence of atherogenic lipoproteins including oxLDL.
1122-172 Homocysteine Induced Endothelial Cell Damage 
Through NF-κB Activation and Monocyte 
Chemoattractant Protein-1 and Vascular Cell Adhesion 
Molecule-1 Expression
Hae-Young Lee, Dae-Gyun Park, Hyo-Soo Kim, Young-Bae Park, Seoul National 
University College of Medicine, Seoul, South Korea
Background & Aim: Homocysteine is known to damage endothelial cells by oxidative
stress, most studies were however performed with excessively high concentration. In
order to evaluate the action mechanism of homocysteine in clinically relevant concentra-
tion, S-adenosylhomocysteine (SAH) was induced intracellularly and NF-κB, the impor-
tant transcriptional regulator for oxidative stress, and its downstream mediators, MCP-1
and VCAM-1 expressions, were evaluated.
Methods: SAH was formed in human umbilical vein endothelial cells (HUVECs) by
administering homocystine, adenosine, and erythro-9-(2-hydroxy-3-nonyl) adenine to the
culture media and HUVECs were incubated for 72 hours. Intracellular reactive oxygen
species (ROS) formation was quantified by fluorescent intensity of dichlorofluorescin
(DCF) with confocal microscope. The proliferation and survival of HUVECs were evalu-
ated by [3H]-Thymidine uptake and MTT assay. NF-κB activity, MCP-1 secretion and
VCAM-1 expression were assayed by EMSA, ELISA and Western blot respectively.
Results: HUVECs showed atrophic change after intracellular SAH formation and the
deterioration was progressive according to time and concentration.
Intracellular ROS production evaluated by DCF fluorescence was increased. The cell
proliferation rates evaluated by [3H]-Thymidine uptake were decreased both in 40µM
SAH group (148 ± 47 CPM) and 200µM SAH group (139 ± 50 CPM) (control=207 ± 22
CPM) and the cell survival rates assayed by MTT uptake were also decreased both in
lower and higher SAH groups (156 ± 12 CPM and 106 ± 13 CPM) compared with control
(185 ± 10CPM).
NF-κB was activated by SAH induction, which was followed by increased MCP-1 secre-
tion and VCAM-1 expression.
Conclusion: We have shown that homocysteine damaged endothelial cells even in clini-
cally relevant concentrations through sustained exposure with intracellular SAH forma-
tion. And intracellular ROS production and NF-κB activation were observed and MCP-1
secretion and VCAM-1 expression might lead to inflammatory response in SAH-treated
endothelial cells. These data identified novel mechanism of homocysteine inducing
endothelial cell damage.
1122-173 Changes in Innate and Adaptive Humoral Immune 
Responses and Indices of Atherosclerosis in Aging
Kuang-Yuh Chyu, Paul C. Dimayuga, Stephanie M. Babbidge, Juliana Yano, Odette 
Reyes, Bojan Cercek, Prediman K. Shah, Cedars-Sinai Medical Center, Los Angeles, CA
Background: Immunization against atherosclerosis is a promising therapy but the natu-
ral course of immune responses against oxLDL during aging is not known. We hypothe-
sized that aging alters innate or adaptive immune responses to oxLDL modulating the
progression of atherosclerosis and plaque phenotype in apoE -/- mice. Method: Mice on
Western diet were sacrificed at 15-17, 36 or >50 weeks of age. Descending aorta was
stained en-face for lipids. Plaque lipid, macrophage and collagen content were evaluated
in the aortic sinus. Innate immune response was assessed using anti Cu-oxLDL and anti
phosphorylcholine (PC) IgM and adaptive immune response to oxLDL was assessed
using anti MDA-LDL and Cu-oxLDL IgG titers. Splenic cytokines were evaluated using
RT-PCR. Result: (Table) Aging was associated with increased atherosclerotic burden
and collagen content with decreased macrophage and plaque lipid. MDA-LDL IgG
increased in the 36 weeks group but reduced in mice >52 weeks. Cu-oxLDL and PC-IgM
increased significantly with age with cross-reactivity to each other. Cu-oxLDL IgG
increased with age with no isotype specificity. Splenic T-helper cytokine mRNA expres-
sion also increased with age. Conclusion: Innate immune response as indicated by anti-
body titers to CuoxLDL and PC is associated with increased plaque sizes and a more
stable phenotype. 
†Densitometric units relative to β-actin; ¶p<0.05 vs. 36 wk; ‡p<0.05 vs. 17 wk; IgG and
IgM ELISAs n=5 for 15-17 and 36 weeks and n=6 for >52 weeks; expressed as OD 405
1122-174 Thrombin and Histamine Stimulate Phosphorylation of 
Endothelial Nitric Oxide-Synthase via an Akt-
Independent, AMP-Activated Kinase-Dependent 
Pathway
Brynhildur Thors, Haraldur Halldórsson, Gudmundur Thorgeirsson, Institute of 
Pharmacy, Pharmacology and Toxicology, University of Iceland, Reykjavik, Iceland, 
Landspitali-University Hospital, Reykjavik, Iceland
Background: The protein kinase Akt is involved in vascular development and several
endothelial functions, including activation of endothelial NO-synthase (eNOS) and pro-
motion of endothelial cell survival. Recently we have found that although Akt-phosphory-
lation is inhibited by the G-protein activators thrombin and histamine these agonists
stimulate phosphorylation of eNOS on Ser1179. The purpose of this study was to exam-
ine the role of other protein kinases in mediating this Akt-independent phosphorylation of
eNOS.
Age 15-17 weeks 36 weeks >52 weeks
% En-face area 0.5+0.3 n=6 24.1+4.3‡ n=8 46+13.5‡¶ n=6
Sinus plaque (mm sq) 0.31+0.06 n=5 0.65+0.1‡ n=5 1.13+0.14‡¶ n=6
% Plaque Lipid 29.6+7.5 n=6 20.5+4.7‡ n=8 11.1+4.2‡¶ n=6
% Macrophage 14.2+4.5 n=6 10.2+2.7 n=8 5.1+3.1‡¶ n=6
% Collagen 27.7+7.1 n=5 38.4+3.0 n=7 43.4+14‡ n=6
MDA-LDL IgG 0.063+0.024 0.129+0.036‡ 0.064+0.044¶
Cu-oxLDL IgG 0.125+0.036 0.435+0.201 1.049+0.560‡¶
Cu-oxLDL IgM 0.316+0.070 0.560+0.286 1.011+0.356‡
PC IgM 0.419+0.068 0.628+0.276 0.923+0.308‡
IL-4† n=4 0.008+0.004 0.023+0.005 0.062+0.029‡¶
IFN-γ€ n=4 0.015+0.006 0.04+0.014 0.128+0.095‡
IL-10† n=3 0.025+0.018 0.113+0.175 0.247+0.109
























Methods: Human umbilical endothelial cells were cultured to confluence and stimulated
with either thrombin or histamine with or without inhibitors of protein kinases possibly
involved in the regulation of eNOS activity. Phosphorylation of eNOS was analyzed with a
phosphospecific eNOS(Ser1179) antibody by Western blotting.
Results: Stimulation (using short term 12-O-tetradecanoylphorbol-13-acetate (TPA) treat-
ment) or inhibition (by GF 109203X) of protein kinase C had no effect on eNOS phospho-
rylation and neither did the Rho-dependent kinase inhibitorY27632, the calmodulin
kinase inhibitor KN-62, the ERK-inhibitor PD98059 or the p38 inhibitor SB203580. Con-
versly, H89 which is an inhibitor of both protein kinase A (PKA) and the AMP-activated
kinase (AMPK) strongly inhibited eNOS phosphorylation. Neither thrombin nor histamine
caused a rise in endothelial cyclic-AMP and neither forskolin nor dibutyryl-cyclic-AMP
affected eNOS phosphorylation contradicting the possible role of PKA in the activation
pathway. On the other hand, thrombin and histamine caused phosphorylation of the
AMPK downstream substances acetyl-CoA carboxylase and elongation factor-2.
Conclusion: The G-protein activators thrombin and histamine stimulate eNOS phospho-
rylation on Ser1179 via an Akt-independent, AMPK-dependent pathway.
1122-175 Ox-Low-Density Lipoprotein Are Potent Antigens for 
Dendritic Cell in Plaque Instability: Role of 
Lipoxygenase-1
Fabrizio Clementi, Sandro Grelli, Ruggiero Mango, Massimo Federici, Luigi Franchi, 
Andrea Amato, Giovanni Battista Forleo, Gaetano Chiricolo, Massimo Marchei, Lucia De 
Luca, Mark Gallagher, Cartesio Favalli, Renato Lauro, Giuseppe Novelli, Francesco 
Romeo, University of Rome Tor Vergata, Rome, Italy
Experimental data identify ox-LDL has the most important antigens in atherosclerosis
and plaque rupture. Recently, we identified lectin-like oxidized low-density lipoprotein
receptor (LOX-1), as a susceptibility gene for myocardial infarction. Experimental data
had shown that ox-LDL are a potent stimulus for maturation of monocyte derived den-
dritic cells (MDDC). MDDC stimulated by ox-LDL are able to activate T-lymphocyte
toward a Th1 response similar to that observed during the acute phases of coronary
instability.
We hypothesized that LOX-1 could be involved in ox-LDL induced maturation of MDDC
and could drive the activation of immune system toward a Th1 response.
Methods: peripheral blood monocyte were collected from healthy donors and CD14+
cells were cultured in the presence of GM-CSF and IL-4 to differentiate in immature den-
dritic cells and stimulated at day 5 of differentiation by ox-LDL (80 micg/ml) or
lipopolysaccharide (LPS) (1 ng/ml) in the presence and absence of a blocking mono-
clonal antibody of LOX-1 (10 micg/ml). Analysis of CD-80, HLA-DR, CD-86, CD-14,
CD1a were performed by flow-cytometry at day 6. Capture of DiI labelled ox-LDL by
mature dendritic cells were studied by flow-cytometry after maturation induced by LPS or
ox-LDL in the presence or absence of LOX-1 antibody.
Results: Pre-treatment with LOX-1 antibody negatively modulates the differentiation of
MDDC induced by ox-LDL but not by LPS. Induction of maturation induced by LPS or ox-
LDL reduced the amount (mean fluorescence intensities, MFI) of DiI-labelled ox-LDL
captured by dendritic cells. Pre-treatment at day 6 of maturation with LOX-1 antibody
have no effect in cells stimulated with LPS, conversely in cells stimulated with ox-LDL,
LOX-1 antibody reduced by 75% the binding of DiI labelled ox-LDL.
Conclusions: we identified LOX-1 as one of the major receptor involved in up-take of ox-
LDL and maturation of MDDC. Moreover activation of MDDC lead to a reorganization of
membrane receptor with a dominant role of LOX-1. Inhibition of dendritic cells activation
induced by ox-LDL by the use of LOX-1 antibody could have important role in clinical sta-
bilization of patients presenting with ACS.
1122-176 NAD(P)H Dependent Superoxide Production in Human 
Platelets: The Role of Angiotensin II and Protein Kinase 
C
Sinead M. Hughes, Rick Plumb, Naglaa El- Sherbeeny, Lana J. Dixon, Adrian Devine, 
William J. Leahy, Gary E. McVeigh, Queen's University, Belfast, United Kingdom
Background: In health Endothelial Cells (ECs) have tightly controlled pathways for the
production and degradation of Superoxide (02.-). In hypertension there seems to be loss
of this control in animal/ in vtiro studies, with an increase in 02.- production mainly by the
NAD(P)H oxidase system. This increase in 02.- appears to be stimulated by a Protein
Kinase C (PKC) mediated effect on Angiotensin II (AT II) acting via the AT II type 1 recep-
tor. Platelets are known to release 02.-.In this study we postulate that the systems
responsible for 02.- production in ECs are also responsible in platelets making the latter
an excellent moel for the study of ECs.
Method:We studied 20 patients with known essential hypertension who were off medica-
tion for 4 weeks. Platelet suspensions were prepared by sequential centrifugation and
standardised assays were stimulated with AT II or Phorbol Myristate Acetate (PMA). Val-
sartan (an AT II type 1 receptor inhibitor), DPI/ Quinacrine ( a flavoprotein oxidoreductase
inhibitor) or Chelerythrine (a PKC inhibitor) were added to the platelet samples from each
individual.02.- was measured using the lucigenin-enhanced chemiluminescent technique.
Results: AT II and PMA stimulated platelet 02.- production. This was markedly reduced by
Valsartan, Chelerythrine and DPI/ Quinacrine. Conclusions: AT II stimulates an increase
in platelet production of 02.- from NAD(P)H oxidase predominantly via the AT II type 1
receptor. This is at least in part mediated by PKC activation. Platelets are thus an excel-
lent model of ECs for the study of 02.- production, in terms of both ease of accessibility
and similarity of systems.
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1123-177 Treatment for Children With Idiopathic Pulmonary 
Arterial Hypertension: Long-Term Survival and 
Outcomes
Delphine Yung, Greg Maislin, Allison Widlitz, Erika S. Berman Rosenzweig, Kelly 
Schmitt, Daniela Brady, Ellen O'Brien, Diane Kerstein, Evelyn M. Horn, Robyn J. Barst, 
Columbia University College of Physicians and Surgeons, New York, NY
Background: Treatment for idiopathic pulmonary arterial hypertension (IPAH) in children
has been calcium channel blockers (CCB) for acute responders (AR) with vasodilator
testing and chronic epoprostenol for nonresponders (NR). We sought to determine fac-
tors associated with long-term survival and treatment success, i.e. without death or trans-
plant, and without transition to epoprostenol for patients on CCB.
Methods: A previously identified cohort of 79 patients under age 16 diagnosed with IPAH
between 1982 and 1995 at Columbia University was followed through 2002.
Results: For AR, survival rates at 1, 5 and 10 years were 97%, 97%, and 81%, respec-
tively. For AR, success rates on CCB at 1, 5 and 10 years were 84%, 68%, and 47%. Sur-
vival rates on epoprostenol at 1, 5 and 10 years were 94%, 81%, and 61%, respectively.
Success rates on epoprostenol at 1, 5 and 10 years were 89%, 63%, and 45%. With mul-
tivariate analysis, baseline variables associated with success on CCB were AR status,
NYHA class I, II, or III, and right atrial pressure. When AR status changed to NR status,
success on CCB decreased significantly. Both survival and success on epoprostenol
were only associated with age at the start of epoprostenol.
Conclusion: These findings suggest that children with IPAH who are AR should be
treated with CCB therapy with transition to epoprostenol if they change to NR status.
Epoprostenol therapy should be considered in patients with higher NYHA class, and list-
ing for transplantation should be considered in older patients. 
1123-178 The Lonflit Study: Evaluation of Venous Thrombosis in 
5,000 Long-Haul Passengers
Belcaro Giovanni, Cesarone Maria Rosaria, Chieti University, San Valentino (Pe), Italy
The LONFLIT studies have evaluated the frequence of deep venous thrombosis (DVT)
and edema in subjects flying 7-12 hours. By ultrasound femoral, popliteal, soleal veins
were scanned. A global analysis was performed to evaluate the frequence of DVT in a
population sample including 5000 passengers; 4922 (age range 25-69; M:F=43% vs
57%) completed the study. Subjects were divided in high, moderate and low risk for DVT
(Am College of Cardiology Guidelines). Global analysis indicates the incidence of clots
detected after flights: 3.25% of subjects had a clot; most subjects (93.66%) had a vari-
able range of leg edema. An epidemiological evaluation (questionnaires) on 6448 pas-
sengers, indicates that 54% of subjects flying between 7-12 hours (age range 25-75) can
be considered at low-risk, 35% at moderate and 11% at high risk. The possible incidence
of DVT could be extrapolated to a number between 2 and 3% for the general flying popu-
lation. Our analysis excluded younger subjects (<25) and subjects older than 75 who
constitute a significant number of passengers. As 20 000 000 travellers fly every year for
more than 10 hours the problem should be considered with attention. The finding small
(<1 cm) vein clots, which may be spontaneously lysed in hours is an interesting observa-
tion of doubtful clinical value. Prevention with specific stockings, low-molecular weight
heparin (Lovenox) and antithrombotic drugs, as shown in randomized trials reduce DVT
incidence particularly in high-risk subjects.
FREQUENCE OF DVT AND EDEMA
RISK LEVEL NUMBER LOST % WITH DVT NUMBER OF DVT % WITH EDEMA
LOW 1476 58 1.35 20 88
MODERATE 1787 61 2.5 45 93
HIGH 1659 54 5.9 98 100
TOTAL 4922 173 3.25 163 93.66
